Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilotAug 7Weekly roundup, 2 itemsArcus Biosciences, Inc.casdatifan
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Summit Therapeutics discloses going concern doubt alongside $380 million stock offeringJul 23FinancingivonescimabSummit Therapeutics
Sign inSign in